TNF and inflammatory bowel disease: Monoclonal antibodies targeting proinflammatory cytokines, such as adalimumab (a kind of TNF-α antibody), are also commonly used in the clinic for the advanced stage of IBD [6], while the efficacies of these antibody drugs are not so satisfactory because multiple inflammatory cytokines and signaling pathways are involved during IBD development [7], and just targeting only one cytokine is not sufficient for treatment.